Terrific @CTADconference in Madrid. Some thoughts: 1. Trontinemab looks good, but let’s be cautious for Phase 3 with bigger sample and in case ARIA is delayed.
3
1
6
1K
1
2. Plasma pT217 has terrific PPV for amyloid PET in cognitively impaired population, but we may want PET anyway because we will want to track clearance. Best use of pTau217 may be its terrific NPV in cognitively unimpaired population if prevention studies are positive.
@andrewmstern @CTADconference Thanks for sharing!
